Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: Effects on the course of Alzheimer's disease

Biological Psychiatry

Volumn 49, Issue 3, 2001, Pages 289-299

  Coyle, Joseph ^a,c   Kershaw, Paul ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^c MCLEAN HOSPITAL   (United States)

Author keywords

Activities of daily living; Alzheimer's disease; Behavioral symptoms; Galantamine; Nicotinic receptors

Indexed keywords

ACETYLCHOLINE; AMYLOID BETA PROTEIN; CHOLINESTERASE INHIBITOR; GALANTAMINE; NICOTINIC RECEPTOR;

ALLOSTERISM; ALZHEIMER DISEASE; ANOREXIA; BEHAVIOR; CHOLINESTERASE INHIBITION; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME INHIBITION; HUMAN; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; STATISTICAL ANALYSIS; TREATMENT OUTCOME; VOMITING;

AGED; ALLOSTERIC REGULATION; ALLOSTERIC SITE; ALZHEIMER DISEASE; BRAIN; CHOLINESTERASE INHIBITORS; CLINICAL TRIALS, PHASE III; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; GALANTAMINE; HUMANS; MULTICENTER STUDIES; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, NICOTINIC;

EID: 0035251762     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(00)01101-X     Document Type: Review

References (69)

1. Properties of neuronal nicotinic acetylcholine receptors: Pharmacological characterization and modulation of synaptic function
2. Choline and selective antagonists identify two subtypes of nicotinic acetylcholine receptors that modulate GABA release from CA1 interneurons in rat hippocampal slices
3. Survival in Alzheimer's disease and vascular dementias
4. The cholinergic hypothesis of geriatric memory dysfunction
5. Effectiveness of rivastigmine in Alzheimer's disease. Improvements in functional ability remain unestablished
6. Pharmacological evaluation of novel Alzheimer's disease therapeutics: Acetylcholinesterase inhibitors related to galanthamine
7. Time until institutionalization and death in patients with dementia. Role of caregiver training and risk factors
8. The effects of donepezil in Alzheimer's Disease-results from a multinational trial
9. Patterns of caring for people with dementia in Canada
10. A randomised trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease
11. Dopamine and nicotinic receptor binding and the levels of dopamine and homovanillic acid in human brain related to tobacco use
12. Alzheimer's disease: A disorder of cortical cholinergic innervation
13. Cholinesterase inhibitors: A new class of psychotropic compounds
14. Neuropsychiatric aspects of Alzheimer's disease: The cholinergic hypothesis revisited
15. The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
16. Challenging the cholinergic hypothesis in Alzheimer disease
17. Cholinergic markers in elderly patients with early signs of Alzheimer's disease
18. The US economic and social costs of Alzheimer's disease revisited
19. "Mini-mental state": A practical method for grading the cognitive state of patients for the clinician
20. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease
21. Functional disability in Alzheimer's disease
22. Development of a functional measure for persons with Alzheimer's disease: The disability assessment for dementia
23. Trial designs: Pharmacotherapy of Alzheimer's disease
24. Consensus statement on the upcoming crisis in geriatric mental health
25. Effect of tacrine on behavioral symptoms in Alzheimer's disease: An open-label study
26. Assessing the impact of neuropsychiatric symptoms in Alzheimer's disease: The Neuropsychiatric Inventory Caregiver Distress Scale
27. Stimulation of alpha4beta2 nicotinic acetylcholine receptors inhibits beta-amyloid toxicity
28. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease
29. Observations and suggestions on antidementia drug development
30. Nicotinic acetylcholine involvement in cognitive function in animals
31. Additional benefits to patients with Alzheimer's disease
32. Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease
33. Influence of kinetics of nicotine administration on tolerance development and receptor levels
34. Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors
35. Clinical diagnosis of Alzheimer's disease; report of the NINCDS/ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease
36. The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease
37. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease
38. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease
39. Nicotinic system involvement in Alzheimer's and Parkinson's diseases
40. An algorithm (decision tree) for the management of Parkinson's disease: Treatment guidelines
41. Galantamine in Alzheimer's disease - A 6-month randomized, placebo-controlled trial with a 6-month extension
42. Effect of tacrine on language, praxis, and non-cognitive behavioural problems in Alzheimer's disease
43. Donepezil improves cognition and global function in Alzheimer disease: A 15-week, double-blind, placebo-controlled study
44. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
45. The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial
46. A new rating scale for Alzheimer's disease
47. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial
48. Nicotinic stimulation of [3H]acetylcholine release from mouse cerebral cortical synaptosomes
49. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change
50. Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands
51. Economic considerations in the treatment and management of Alzheimer's disease
52. Are two antidepressant mechanisms better than one?
53. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease
54. A longitudinal study of Alzheimer's disease: Measurement, rate and predictors of cognitive deterioration
55. Effects of different doses of galanthamine, a long-acting acetylcholinesterase inhibitor, on memory in mice
56. A long-acting cholinesterase inhibitor reverses spatial memory deficits in mice
57. Galanthamine, an acetylcholinesterase inhibitor: A time course of the effects on performance and neurochemical parameters in mice
58. A 5-month, randomized, placebo-controlled trial of galantamine in Alzheimer's disease
59. Behavioral disturbance, cognitive dysfunction and functional skill. Prevalence and relationship in Alzheimer's disease
60. Inhibition of acetylcholinesterase activity in human brain tissue and erythrocytes by galantamine, physostigmine and tacrine
61. Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo
62. In vitro effects of various cholinesterase inhibitors on acetyl- and butyrylcholinesterase of healthy volunteers
63. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: A multicentre randomised controlled trial
64. Atypical antipsychotic agents: A critical review